Free Call: 1800 792 676
Seminar Invitation: Pitfalls for SMEs in protecting and claiming incentives for new developments
Presented by:
- Joe Seisdedos (Wrays)
- Bill Charlton (UHY Haines Norton)
- Michael Oon (Swanson Reed)
Join Swanson Reed, UHY Haines Norton and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
| Time | Presentation | Presenter | |
| 7:00am – 7:30am: | Session 1: Protecting Intellectual Property (IP) | Joe Seisdedos | |
| 7:30am – 8:00am: | Session 2: IP & Relevant Tax Considerations | Bill Charlton | |
| 8:00am – 8:30am: | Session 3: R&D Tax Incentives | Michael Oon | |
| 8:30am – 9:00am: | Session 4: Panel Q&A and Networking Opportunity | ||
| Joe Seisdedos | Bill Charlton | Michael Oon |
 |
 |
 |
| View Joe’s bio | View Bill’s bio | View Michael’s bio |
Brisbane R&D Tax Seminar:
Wednesday, 18th June 2014
7am – 9am
Swanson Reed Boardroom
Level 11, 42-60 Albert St
Brisbane, 4000
Cost: Free!
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 07 3221 1499
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
Latest News
Imugene Ltd receives $6.5M R&D Tax Offset Refund
Melbourne-based Imugene Ltd announced in January 2022 the receipt of the company’s FY21 R&D Tax Offset refund of $6,541,921. The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including: Granting of additional patents for the company’s HER-Vaxx Immunotherapy in China and South Korea; Completion of Phase 1a trial of immunotherapy PD1-Vaxx; US Food and Drug Administration (FDA) consent for clinical trials for its oncology treatments. In recent […]
ATO Release Finalised Tax Tuling TR 2021/5 (At Risk Rule)
Under SECT 355.405 ITAA97, an entity cannot claim R&D expenditure in situations where: (a) when an entity incurs R&D expenditure, consideration has been received, or was reasonably expected to be received: o as a direct or indirect result of the expenditure being incurred; and o regardless of the results of the activities on which the expenditure is incurred; and (b) that consideration is equal to or greater than the expenditure. The spirit of this provision is to ensure companies only […]
Quick Contact
News & Research
News & Research
News & ResearchImugene Ltd receives $6.5M R&D Tax Offset Refund
Melbourne-based Imugene Ltd announced in January 2022 the receipt of the company’s FY21 R&D Tax Offset refund of $6,541,921. The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent […]
ATO Release Finalised Tax Tuling TR 2021/5 (At Risk Rule)
Under SECT 355.405 ITAA97, an entity cannot claim R&D expenditure in situations where: (a) when an entity incurs R&D expenditure, consideration has been received, or was reasonably expected to be received: o as a direct or indirect result of the […]
